

Final Agenda
25th meeting of the Committee for Risk Assessment

4-7 June 2013
ECHA Conference Centre (Annankatu 18, Helsinki)
4 June: starts at 9:00
7 June: ends at 13:00

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

RAC/A/25/2013
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Report from other ECHA bodies and activities

- a) Report on RAC 24 action points, written procedures and other ECHA bodies

RAC/25/2013/01
For information

- b) RAC work plan for all processes

For information

Item 5 – Harmonised classification and labelling (CLH)

5.1 Sensitisation criteria following the 2nd ATP to the CLP Regulation
For discussion and agreement

5.2 CLH dossiers

- a) Etridiazole
b) Metosulam
c) Organic acids
 a. Octanoid acid,

- b. Nonanoic acid,
- c. Decanoic acid
- d) Diisohexylphthalate (DIHP)
- e) Imazalil
- f) Tebuconazole
- g) Spirotetramat
- h) Dimethenamid-P
- i) Carvone
- j) Tembotrione
- k) Flonicamid

For discussion/adoption

5.3 Appointment of RAC (co-)rapporteurs for CLH dossiers

RAC/25/2013/02 (confidential room document)

For agreement

5.4 General and procedural CLH issues

RAC/25/2013/05

For information/discussion

Item 6 – Restrictions

6.1 General restriction issues

For information

6.2 Restriction Annex XV dossiers

- a) Lead in consumer articles – 1st version of RAC draft opinion

For discussion

- b) 1-Methylpyrrolidin-2-one (NMP) – outcome of the conformity check

For agreement

6.3 Appointment of (co-)rapporteurs for restriction dossiers

RAC/25/2013/03 (confidential)

For information/agreement

Item 7 – Authorisation

7.1 Capacity building

For information

7.2 Recommendation of the review period in applications for authorisation

RAC/25/2013/08

For discussion/agreement

7.3 Revised working procedure for appointment of (co-)rapporteurs for authorisation applications

RAC/25/2013/04

For discussion/agreement

7.4 Appointment of (co-)rapporteurs for authorisation applications (closed session)

RAC/25/2013/06 (confidential room document)

For agreement

Item 8 – RAC Manual of Conclusions and recommendations

RAC/25/2013/07

For information/agreement

Item 9 – AOB

- a) Stockholm Convention decision on HBCDD - relevance for Annex XIV

Item 10 – Action points and main conclusions of RAC-24

Table with Conclusions and Action points from RAC-24

For adoption